NANOSONICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.75 AUD | -0.36% |
|
+1.85% | -37.50% |
| Mar. 15 | Nanosonics Chief Technology Officer to Retire | MT |
| Feb. 26 | Nanosonics Shares Fall 8% as H1 FY24 Revenue Falls 2% to AU$79.6 Million; EPS Slips to AU$0.0202 | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 94.53 and 61.96 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.26 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -37.50% | 543M | B+ | ||
| +8.07% | 219B | B | ||
| +6.59% | 183B | B- | ||
| +11.26% | 133B | B- | ||
| +26.57% | 108B | A- | ||
| +0.65% | 63.06B | A- | ||
| +13.35% | 52.02B | B+ | ||
| -0.62% | 48.2B | B+ | ||
| -0.93% | 40.37B | A | ||
| +11.54% | 39.35B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NAN Stock
- Ratings Nanosonics Limited
